Page 5 - Thomas Eldered News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roar BidCo's outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms On 14 December 2020, EQT IX 1 2 ("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo (the "Offer"). An offer document relating to the Offer was made public on 17 December 2020 (the "Offer Document"). The Offer was subsequently incr...

Electrolux Nomination Committee's proposal for election of board members STOCKHOLM, Feb. 1, 2021 /PRNewswire/ — In preparation for the Electrolux Annual General Meeting on March 25, Electrolux Nomination Committee has decided to propose the re-election of all board members except Kai Wärn, who has declined re-election. Staffan Bohman is proposed to be re-elected as Chairman of the Board of Directors, and Petra Hedengran, Henrik Henriksson, Ulla Litzén, Karin Overbeck, Fredrik Person, David Porter and Jonas Samuelson as Board Members. The Nomination Committee comprises Johan Forssell (...

By Reuters Staff 1 Min Read STOCKHOLM (Reuters) - Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT raised its bid to 232 crowns per share from the 220 crowns it had offered in December. “We consider this revised offer to be highly compelling for Recipharm’s shareholders,” EQT partner Erika Henriksson said in a statement. EQT added that the bid would not be increased further. Recipharm’s board of directors said in a separate statement they unanimously recommend...

路透新闻部 (Adds CEO quote, background) Dec 30 (Reuters) - Recipharm AB and Moderna Inc have finalized a deal under which the Sweden-based company will help manufacture Moderna’s COVID-19 vaccine outside the United States potentially starting early next year, the companies said on Wednesday. Recipharm last month said it had agreed to a preliminary deal with Moderna to fill and seal the packaging for the vaccine, which has recently been authorized for emergency use in the United States. The Swedish company said it will carry out the process in its drug product manufacturing facility loc...

(2) Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The activity will be performed in Recipharm's drug product manufacturing facility located in France. Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it is anticipated that supply will comm...